Market openADR
AstraZeneca/$AZN
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About AstraZeneca
A merger between Astra of Sweden and Zeneca Group of the United Kingdom formed AstraZeneca in 1999. The firm sells branded drugs across a number of major therapeutic areas, including oncology (about 40% of total revenue), cardiovascular, renal, and metabolic (25%), rare disease (17%), and respiratory and immunology (15%). The majority of sales comes from international markets, with the United States representing close to one third of its sales.
Ticker
$AZN
Sector
Trading on
Industry
Pharmaceuticals
Headquarters
Employees
94,300
ISIN
US0463531089
Website
AstraZeneca Metrics
BasicAdvanced
$210B
13.63
$4.97
0.18
$1.52
3.04%
Price and volume
Market cap
$210B
Beta
0.18
52-week high
$87.01
52-week low
$61.24
Average daily volume
6.5M
Dividend rate
$1.52
Financial strength
Current ratio
0.897
Quick ratio
0.694
Long term debt to equity
67.922
Total debt to equity
77.112
Dividend payout ratio (TTM)
63.60%
Interest coverage (TTM)
10.16%
Management effectiveness
Return on assets (TTM)
8.16%
Return on equity (TTM)
19.79%
Valuation
Price to earnings (TTM)
13.627
Price to revenue (TTM)
1.909
Price to book
3.84
Price to tangible book (TTM)
-8.94
Price to free cash flow (TTM)
11.417
Dividend yield (TTM)
2.24%
Forward dividend yield
3.04%
Growth
Revenue change (TTM)
15.48%
Earnings per share change (TTM)
22.71%
3-year revenue growth (CAGR)
9.84%
3-year earnings per share growth (CAGR)
90.42%
3-year dividend per share growth (CAGR)
2.60%
What the Analysts think about AstraZeneca
Analyst Ratings
Analyst ratings (Buy, Hold, Sell) for AstraZeneca stock.
AstraZeneca Financial Performance
Income Statement
Revenues and expenses
QuarterlyAnnual
Q3 24
QoQ growth
Revenue
$37B
-39.75%
Net income
$45B
107.52%
Profit margin
37.65%
6.78%
AstraZeneca Earnings Performance
Earnings per share (EPS)
Company profitability
QuarterlyAnnual
Q4 23
Q1 24
Q2 24
Q3 24
Q4 24
Actual
$3.69
$2.85
$2.45
$2.42
-
Expected
$3.55
$2.61
$2.05
$2.31
$3.94
Surprise
3.94%
9.20%
19.51%
4.63%
-
AstraZeneca News
AllArticlesVideos
BioInvent Announces Updated Phase 2a Triple Combination Arm Data of BI-1206, rituximab, and Calquence for the Treatment of Non-Hodgkin's Lymphoma
Accesswire·3 hours ago
Dr. Scott Gottlieb: What to expect from President Trump's executive order to lower drug prices
CNBC Television·2 days ago
AstraZeneca's Imfinzi delays bladder cancer return in high-risk patients
Proactive Investors·5 days ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
FAQs
What’s the current market cap for AstraZeneca stock?
AstraZeneca (AZN) has a market cap of $210B as of May 14, 2025.
What is the P/E ratio for AstraZeneca stock?
The price to earnings (P/E) ratio for AstraZeneca (AZN) stock is 13.63 as of May 14, 2025.
Does AstraZeneca stock pay dividends?
Yes, the AstraZeneca (AZN) stock pays dividends to shareholders. As of May 14, 2025, the dividend rate is $1.52 and the yield is 3.04%. AstraZeneca has a payout ratio of 63.6% on a trailing twelve-month basis.
When is the next AstraZeneca dividend payment date?
The next AstraZeneca (AZN) dividend payment date is unconfirmed.
What is the beta indicator for AstraZeneca?
AstraZeneca (AZN) has a beta rating of 0.18. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.